Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00420264 · ClinicalTrials.gov registry record · NA
ThermaChoice III Under Local Sedation in the Office Setting
A NA study of Heavy Uterine Bleeding, sponsored by Female Pelvic Medicine & Urogynecology Institute of Michigan.
- Completed
- Registry status
- NA
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT00420264: Completed NA study of Heavy Uterine Bleeding, sponsored by Female Pelvic Medicine & Urogynecology Institute of Michigan.
NCT00420264 is a NA study of Heavy Uterine Bleeding that has completed, run by Female Pelvic Medicine & Urogynecology Institute of Michigan. The registered enrollment target is 21 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00420264, a NA study of Heavy Uterine Bleeding, has completed, sponsored by Female Pelvic Medicine & Urogynecology Institute of Michigan.
- COMPLETED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
Investigational study to determine if an endometrial ablation for heavy uterine bleeding, can be tolerated in the office setting without the use of intravenous medication.
Conditions Studied
Interventions
- DEVICE Uterine Ablation
Study Locations (1)
Michigan
- Grand Valley Gynecologists, PC - Grand Rapids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2005-11 |
| Est. Completion | 2009-05 |
| Phase | NA |
What the finished NCT00420264 record still lists
NCT00420264 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Heavy Uterine Bleeding appearing as the primary indexed condition, and to 1 intervention - of which Uterine Ablation is the first listed.
NCT00420264 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT00420264 about?
NCT00420264 is a clinical study titled "ThermaChoice III Under Local Sedation in the Office Setting". Investigational study to determine if an endometrial ablation for heavy uterine bleeding, can be tolerated in the office setting without the use of intravenous medication.
What is the current status of trial NCT00420264?
This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2005-11. Estimated completion is 2009-05.
What conditions does trial NCT00420264 study?
This clinical trial studies the following conditions: Heavy Uterine Bleeding.
What interventions are being tested in trial NCT00420264?
The interventions under investigation include: Uterine Ablation (DEVICE).
Who is sponsoring clinical trial NCT00420264?
This trial is sponsored by Female Pelvic Medicine & Urogynecology Institute of Michigan, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00420264 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heavy Uterine Bleeding
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00420264's enrollment target sits among peer trials
21 1762nd of 2000 higher than 233 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia